Skip to main navigation

Skip to Content

Stock
Financials
- SEC Filings
- Financial Reports
News & Events
Corporate Governance
Our Company
IR Resources

Press Releases

Year

Genenta to Present at Upcoming Scientific and Investor Conferences

Sep 06, 2023

Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments

Jul 28, 2023

The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma

Jun 29, 2023

Genenta to Provide Update on Lead Product Temferon™

May 16, 2023

Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing

Apr 26, 2023

Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications

Apr 03, 2023

FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme

Mar 02, 2023

Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement

Feb 07, 2023

Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma Patients

Nov 07, 2022

Genenta Provides First Half 2022 Business Update and Financial Results

Oct 24, 2022

Pagination

Current page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Next page
Last page

Displaying 1 - 10 of 55

Investor Contact

RSS Feeds

Print

ITALY
Dibit – San Raffaele Hospital
Via Olgettina, 58
20132 Milano

UNITED STATES
LaunchLabs – Alexandria Center
430 East 29th Street
New York NY 10016

PARTNERS

genenta-img-san_raffaele

© 2023 Genenta Science. All rights reserved - - Terms and conditions - Privacy Policy